Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 519

Sort by

Sort Order Select

Journal Articles

Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial)

Juan C. Ramos, Joseph A. Sparano, Amy Chadburn, Erin G. Reid, Richard F. Ambinder, Eric R. Siegel, Page C. Moore, Paul G. Rubinstein, Christine M. Durand, Ethel Cesarman, David Aboulafia, Robert Baiocchi, Lee Ratner, Lawrence Kaplan, Adam A. Capoferri, Jeannette Y. Lee, Ronald Mitsuyasu, Ariela Noy

Blood (2020) 136 (11): 1284–1297.

https://doi.org/10.1182/blood.2019003959

Published: 2020

Includes: Supplemental data

Journal Articles

Identification of Potential Chemical Compounds Able to Trigger Enucleation of Immortalized Human Erythroid Cell Lines

Svetlana Soboleva, Ryo Kurita, PhD, Fredrik Ek, PhD, Rita Alves, Roger Olsson, PhD, Yukio Nakamura, MD PhD, Kenichi Miharada, PhD

Blood (2019) 134 (Supplement_1): 951.

https://doi.org/10.1182/blood-2019-128427

Published: 2019

Journal Articles

Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma

Alex F. Herrera, MD, Lu Chen, PhD, Leslie L. Popplewell, MD FRCPA, Lihua E Budde, MD PhD, Matthew Mei, MD, Saro H. Armenian, DO, MPH, Justin Darrah, MD, Liana Nikolaenko, MD, Robert W. Chen, MD, Lacolle Peters, Neena Kennedy, Steven Rosen, MD, Stephen J Forman, MD, Larry W Kwak, MD PhD

Blood (2019) 134 (Supplement_1): 759.

https://doi.org/10.1182/blood-2019-123163

Published: 2019

Journal Articles

Machine Learning Prediction for Complete Response to Hypomethylating Agents with or without Additional Agents in Patients with Newly Diagnosed Myelodysplastic Syndrome

Koji Sasaki, MD, Guillermo Montalban Bravo, MD, Rashmi Kanagal-Shamanna, MD, Elias Jabbour, MD, Farhad Ravandi, MD, Tapan M. Kadia, MD, Kiran Naqvi, MDMPH, Naval G. Daver, MD, Sherry A. Pierce, BSN, BA, Koichi Takahashi, MD, Courtney D. DiNardo, MDMSc, Graciela M. Nogueras González, MPH, Keyur Patel, MD PhD, Kelly Soltysiak, PhD, Junya Sato, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 1720.

https://doi.org/10.1182/blood-2019-130155

Published: 2019

Journal Articles

Integrative Analysis of FISH, Transcriptomics and Mutational Status Predicts Responsiveness to Novel Agents in Multiple Myeloma

Cecilia Bonolo De Campos, PhD, Caleb K Stein, PhD, Nathalie Meurice, PhD, Laura Ann Bruins, BS, Joachim L Petit, PhD, Alysia N Polito, BS, Gregory J Ahmann, BS, Shulan Tian, MS, PhD, P. Leif Bergsagel, MD, Esteban Braggio, PhD, A. Keith Stewart, MB, ChB

Blood (2019) 134 (Supplement_1): 574.

https://doi.org/10.1182/blood-2019-130977

Published: 2019

Journal Articles

High Dependence on Medicare and Foundation Grant Assistance Among Patients with Hematologic Malignancies Receiving Novel Oral Therapeutics

Erlene K. Seymour, MD, Lucius Daniel, Eva Pointer, MS, Stephen T. Smith, Charles A. Schiffer, MD

Blood (2019) 134 (Supplement_1): 64.

https://doi.org/10.1182/blood-2019-128905

Published: 2019

Journal Articles

Sex Differences in Multiple Myeloma Biology and Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial

Sarah Anne Bird, David Cairns, MSc, PhD, Faith E. Davies, MD, Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD, Gordon Cook, Mark T Drayson, MB ChB, PhD FRCPath, Walter M Gregory, PhD, Matthew Jenner, MBBS, MRCP, FRCPath, John R Jones, MD, Martin F. Kaiser, Roger G. Owen, MD, Nigel H. Russell, MD, Gareth Morgan, MDPhDFRCP, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath

Blood (2019) 134 (Supplement_1): 4374.

https://doi.org/10.1182/blood-2019-128041

Published: 2019

Journal Articles

Differentiation Therapy with Novel Epigenetic Inhibitors in Acute Myeloid Leukemia

Edurne San Jose, Naroa Gimenez-Camino, Obdulia Rabal, Estibaliz Miranda, Leire Garate, Fernando Garcia, Ana Alfonso Pierola, MD PhD, Sara Villar, Jose J. Rifon Roca, MD, Antonio Pineda-Lucena, Bruno Paiva, PhD, Javier Muñoz, Jesús San-Miguel, Julen Oyarzabal, PhD, Xabier Agirre, PhD, Felipe Prósper, MD PhD

Blood (2019) 134 (Supplement_1): 3762.

https://doi.org/10.1182/blood-2019-125578

Published: 2019

Journal Articles

HDAC8 Maintain Cytoskeleton Integrity Via Homologous Recombination and Represent a Novel Therapeutic Target in Multiple Myeloma

Zuzana Chyra, PhD, Maria Gkotzamanidou, MD PhD, Masood A. Shammas, PhD, Vassilis L. Souliotis, PhD, Yan Xu, MD, Mehmet K. Samur, PhD, Aaron B. Beeler, PhD, Roman Hajek, MD, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD

Blood (2019) 134 (Supplement_1): 4385.

https://doi.org/10.1182/blood-2019-130700

Published: 2019

Journal Articles

Mogamulizumab within 55 Days of Allogeneic Transplant: A Report of 3 Cases

Mary Jo Lechowicz, MD, Dolores Caballero, MD PhD, Mollie Leoni, MD, Marilyn Tabachri, RN, BSN, Fiona Herr, PhD, Zanetta S. Lamar, MD

Blood (2019) 134 (Supplement_1): 5297.

https://doi.org/10.1182/blood-2019-129302

Published: 2019

Journal Articles

Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study

Youn H. Kim, MD, Martine Bagot, MD PhD, Pier Luigi Zinzani, MD PhD, Madeleine Duvic, MD, Stephen Morris, MBBS, MRCP, FRCR, Ellen Kim, MD, Amy Musiek, MD, Pablo L. Ortiz-Romero, MD PhD, Craig Elmets, MD, Herbert A. Eradat, MDMS, Nina Magnolo, MD, Julia Scarisbrick, MD, Stéphane Dalle, MD PhD, David C. Fisher, MD PhD, Michi Shinohara, MD, Brian Poligone, MD PhD, Barbara Pro, MD, Pietro Quaglino, MD, Nishitha Reddy, MD MSCI, Brigitte Dreno, MD, Larisa J Geskin, MD, Ahmad S Halwani, MD, Amit Khot, MD, Marie Beylot-Barry, MD PhD, Neil Korman, MD, Frederick Lansigan, MD, Steven M. Horwitz, MD, Zanetta S. Lamar, MD, Alison J. Moskowitz, MD, Jillian Wells, MD, Oleg E. Akilov, MD PhD, Dolores Caballero, MD PhD, Richard Cowan, MBBS, MD MRCP, FRCR, Reinhard Dummer, MD, Mary Jo Lechowicz, MD, Francine M. Foss, MD, Lars Iversen, MD, Tomomitsu Miyagaki, MD PhD, Ryan Wilcox, MD, Pierluigi Porcu, MD, Maarten Vermeer, MD PhD, Sunil Abhyankar, MD, Yukihiko Kato, MD PhD, Theresa Pacheco, MD, Shigetoshi Sano, MD PhD, Basem M. William, MRCP,MD, Timothy S. Fenske, MD, Noriko Fukuhara, MD PhD, Koji Habe, MD PhD, Toshihisa Hamada, MD PhD, Eiji Kiyohara, MD PhD, Bryone J. Kuss, MBBS, PhD FRACP, FRCPA, Adam Lerner, MD, Lawrence Mark, MD PhD, Javier Munoz, MD, Hiroyuki Okamoto, MD PhD, Christiane Querfeld, MD PhD, Jiro Uehara, MD, Hisashi Uhara, MD PhD, Kentaro Yonekura, MD PhD, Auris Huen, MD, Kensei Tobinai, MD PhD, Yoshiki Tokura, MD PhD, Erin Boh, MD PhD, Jan Nicolay, MD, Hidefumi Wada, MD, Mollie Leoni, MD, Takahiro Ito, MSc, Fiona Herr, PhD, Lubomir Sokol, MD PhD

Blood (2019) 134 (Supplement_1): 5300.

https://doi.org/10.1182/blood-2019-122778

Published: 2019

Journal Articles

In silico Prediction Followed By in Vitro validation Identifies the Survivin Inhibitor YM155 As a Potent Secondary Drug Against Pi-Resistant Myeloma

Harish Kumar, PhD, Ujjal Kumar Mukherjee, PhD, Li Chen, PhD, Amit Kumar Mitra, PhD MSc, BSc

Blood (2019) 134 (Supplement_1): 5543.

https://doi.org/10.1182/blood-2019-131923

Published: 2019

Journal Articles

Phase I Study of Pracinostat in Combination with Gemtuzumab Ozogamicin (PraGO) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Talha Badar, MD, Guru Subramanian Guru Murthy, MD, Lyndsey Runaas, MD, Karen-Sue B. Carlson, MD PhD, Laura C. Michaelis, MD, Alexandra M. Harrington, MDMT(ASCP), Ehab L. Atallah, MD, Sameem Abedin, MD

Blood (2019) 134 (Supplement_1): 5068.

https://doi.org/10.1182/blood-2019-123237

Published: 2019

Journal Articles

Restore the Secretion and Activity of Factor VIII Mutants By Proteostasis Regulator

Wei Wei, MD PhD, Zhigang Liu, PhD, Bin Zhang, PhD

Blood (2019) 134 (Supplement_1): 1104.

https://doi.org/10.1182/blood-2019-129156

Published: 2019

Journal Articles

CCS1477: A Novel Small Molecule Inhibitor of p300/CBP Bromodomain for the Treatment of Acute Myeloid Leukaemia and Multiple Myeloma

Nigel Brooks, PhD, Meera Raja, PhD, Barbara W Young, PhD, Gary J Spencer, PhD, Tim CP Somervaille, MD PhD, Neil A Pegg, PhD

Blood (2019) 134 (Supplement_1): 2560.

https://doi.org/10.1182/blood-2019-124707

Published: 2019

Journal Articles

Title - Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); Long Term Second Primary Malignancy (SPM) Incidence in the Context of Lenalidomide Maintenance

John R Jones, MD, David Cairns, MSc, PhD, Charlotte Pawlyn, BA,PhDMBBChir,MRCP,FRCPath, Faith E. Davies, MD, Rachel Sigsworth, Matthew Jenner, MBBS, MRCP, FRCPath, Martin F. Kaiser, Rebecca Mottram, BA, BSc, Mark T Drayson, MB ChB, PhD FRCPath, Gordon Cook, Walter M Gregory, PhD, Roger G. Owen, MD, Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD, Graham Jackson, MA, MB BS, FRCP, FRCPath, MD, Gareth Morgan, MDPhDFRCP

Blood (2019) 134 (Supplement_1): 3132.

https://doi.org/10.1182/blood-2019-127469

Published: 2019

Journal Articles

Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS)

Guillermo Garcia-Manero, MD, Shyamala C. Navada, MD, Pierre Fenaux, MD PhD, Patrick S. Zbyszewski, MBA, Afoluso Ronnee Adesanya, MD, Nozar Azarnia, PhD, Steven M. Fruchtman, MD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 4268.

https://doi.org/10.1182/blood-2019-132149

Published: 2019

Journal Articles

A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatment Interval (DTI) and Pre-Protocol Systemic Therapy on Outcomes

Juan Carlos Ramos, MD BS, Joseph Sparano, MD, Page C. Moore, PhD, Eric Siegel, Jeannette Y Lee, PhD, Erin G. Reid, MD MS, Richard F. Ambinder, MD, Amy Chadburn, MD, Paul G. Rubinstein, MD, Christine Durand, Ethel Cesarman, MD PhD, Lee Ratner, MD PhD, Robert A Baiocchi, MD PhD, David M. Aboulafia, MD, Lawrence D Kaplan, MD, Adam Capoferri, Ronald T. Mitsuyasu, MD, Ariela Noy, MD

Blood (2019) 134 (Supplement_1): 1588.

https://doi.org/10.1182/blood-2019-129687

Published: 2019

Journal Articles

Phase 1 Study of Decitabine and Vorinostat Followed By Fludarabine, Cytarabine and G-CSF (FLAG) in Children, Adolescents and Young Adults with Relapsed/Refractory AML: Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium

Lauren Pommert, MDMS, Deepa Bhojwani, MD, Richard Sposto, PhD, Ellynore Florendo, Eric Schafer, MD, Nathan Gossai, MD, Van Thu Huynh, MD, Sridhar Rao, MD PhD, Michael J. Burke, MD

Blood (2019) 134 (Supplement_1): 1325.

https://doi.org/10.1182/blood-2019-127298

Published: 2019

Journal Articles

A Prospective Cohort of Black Patients with Mycosis Fungoides and Sézary Syndrome: Subset Analysis of the Mavoric Trial

William T Johnson, DO, Saritha Kartan, MD, Neda Nikbakht, MD PhD, Pierluigi Porcu, MD

Blood (2019) 134 (Supplement_1): 4766.

https://doi.org/10.1182/blood-2019-126313

Published: 2019

NARROW

Impact of Myc in HIV-associated non-Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC-075 trial)

Identification of Potential Chemical Compounds Able to Trigger Enucleation of Immortalized Human Erythroid Cell Lines

Preliminary Results from a Phase I Trial of Pembrolizumab Plus Vorinostat in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma

Machine Learning Prediction for Complete Response to Hypomethylating Agents with or without Additional Agents in Patients with Newly Diagnosed Myelodysplastic Syndrome

Integrative Analysis of FISH, Transcriptomics and Mutational Status Predicts Responsiveness to Novel Agents in Multiple Myeloma

High Dependence on Medicare and Foundation Grant Assistance Among Patients with Hematologic Malignancies Receiving Novel Oral Therapeutics

Sex Differences in Multiple Myeloma Biology and Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial

Differentiation Therapy with Novel Epigenetic Inhibitors in Acute Myeloid Leukemia

HDAC8 Maintain Cytoskeleton Integrity Via Homologous Recombination and Represent a Novel Therapeutic Target in Multiple Myeloma

Mogamulizumab within 55 Days of Allogeneic Transplant: A Report of 3 Cases

Safety of Mogamulizumab in Mycosis Fungoides and Sézary Syndrome: Final Results from the Phase 3 Mavoric Study

In silico Prediction Followed By in Vitro validation Identifies the Survivin Inhibitor YM155 As a Potent Secondary Drug Against Pi-Resistant Myeloma

Phase I Study of Pracinostat in Combination with Gemtuzumab Ozogamicin (PraGO) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

Restore the Secretion and Activity of Factor VIII Mutants By Proteostasis Regulator

CCS1477: A Novel Small Molecule Inhibitor of p300/CBP Bromodomain for the Treatment of Acute Myeloid Leukaemia and Multiple Myeloma

Title - Myeloma XI Trial for Newly Diagnosed Multiple Myeloma (NDMM); Long Term Second Primary Malignancy (SPM) Incidence in the Context of Lenalidomide Maintenance

Phase 3, Multi-Center, International, Randomized, Double-Blind, Placebo Controlled Study of Oral Rigosertib + Injectable Azacitidine (AZA) Versus Injectable Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS)

A Randomized Trial of EPOCH-Based Chemotherapy with Vorinostat for Highly Aggressive HIV-Associated Lymphomas: Updated Results Evaluating Impact of Diagnosis-to-Treatment Interval (DTI) and Pre-Protocol Systemic Therapy on Outcomes

Phase 1 Study of Decitabine and Vorinostat Followed By Fludarabine, Cytarabine and G-CSF (FLAG) in Children, Adolescents and Young Adults with Relapsed/Refractory AML: Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium

A Prospective Cohort of Black Patients with Mycosis Fungoides and Sézary Syndrome: Subset Analysis of the Mavoric Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only